Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Basic principles in the use of adjuvant therapy.

I C Henderson1

  • 1Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.

Seminars in Oncology
|August 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).

Breast cancer research and treatment·2008
Same author

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2005
Same author

Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2003
Same author

Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.

Clinical cancer research : an official journal of the American Association for Cancer Research·2001
Same author

HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2000
Same author

Purchasing oncology services. Kerr L. White Institute/American Cancer Society Task Force on Purchasing Oncology Services.

Cancer·2000

Adjuvant therapy significantly delays breast cancer death. However, it may not improve survival for women over 50 or younger women receiving tamoxifen, though it improves disease-free survival in node-negative patients.

Area of Science:

  • Oncology
  • Clinical Trials
  • Breast Cancer Research

Background:

  • Adjuvant therapy is a standard treatment for breast cancer.
  • Its efficacy in prolonging survival and improving disease-free survival requires ongoing evaluation.

Purpose of the Study:

  • To evaluate the overall survival and disease-free survival benefits of adjuvant therapy in breast cancer patients.
  • To assess the impact of adjuvant therapy on different age groups and patient subgroups.

Main Methods:

  • Analysis of data from collaborative clinical trials.
  • Comparison of survival outcomes based on treatment regimens, patient age, and nodal status.

Main Results:

  • Adjuvant therapy demonstrably delays breast cancer-related deaths.

Related Experiment Videos

  • No significant survival prolongation was observed for women aged 50 years or older with adjuvant chemotherapy.
  • Tamoxifen did not show improved survival benefits for women younger than 50.
  • Significant improvements in disease-free survival were noted across different chemotherapeutic regimens in node-negative patients.

    • Conclusions:

    • Adjuvant therapy offers a survival benefit by delaying breast cancer mortality.
    • The effectiveness of specific adjuvant treatments varies by patient age and menopausal status.
    • Disease-free survival is a key endpoint improved by adjuvant chemotherapy in node-negative breast cancer.